Of 312 patients presenting with breast cancer to a single clinic, 297 were screened for metastases in skin and nodes, bone, marrow, liver and lungs, using standard clinical, radiological scanning and cytological techniques. Thirty-four patients were found to have overt metastatic disease using these tests. Metastases were demonstrable on chest X-ray in 6.1% of the entire group of patients, on the bone scan in 4.2%, liver scan in 1.5%, liver ultrasound in 1.2% and in the bone marrow in only a single patient; 3.8% had contralateral or supraclavicular lymph node metastases or skin metastases. Twenty-eight of these 34 patients (82%) with overt metastases would have been classed as metastatic had only chest X-ray and clinical examination been carried out.
Introduction
A very small percentage of patients with breast cancer will have a normal expectation of life following surgery for their primary disease (Brinkley & Haybrittle 1975) . The remaining patients will have, at the time of initial presentation, latent residual disease and will be at risk of developing overt metastases. It is important to try to define at the time of presentation those patients who are likely to develop metastases, since they are unlikely to benefit from radical surgery alone and should be considered for systemic treatment.
To date, most published data concern the place of bone scans in the staging of breast cancer at presentation, and a recent collaborative study in which eight centres took part disclosed a 2-20% incidence of metastases (British Breast Group 1978) . In another study 1% were found to have metastases evident on chest X-ray at presentation (Galasco 1972) . There is no clear information in the literature that enables evaluation of many of the other staging tests commonly employed in patients with breast cancer.
For this reason, in all patients presenting with a likely diagnosis of breast cancer, a standard staging system has been carried out to examine the relative efficacy of each test in detecting metastases in patients presenting with breast cancer to a single Combined Breast Clinic. In addition, we have examined the 'lead intervals' provided by tests for bone and liver deposits prior to their development, as proven by radiology and post-mortem respectively. January 1974 to December 1977, 312 patients with breast carcinoma  were referred to the Combined Breast Clinic, St George's Hospital, London SW17. There  were 309 female and 3 male patients, and all except 15 patients were admitted to the Royal  Marsden Hospital, Sutton, Surrey, for complete clinical examination and staging investigations  prior to primary therapy. In addition to a detailed clinical physical examination, the following investigations were done: full blood count and erythrocyte-sedimentation rate (ESR), plasma urea, electrolytes and calcium, serum alkaline phosphatase, alanine transaminase, y-glutamyl transpeptidase (-y-GT) and bilirubin (Autoanalyser), chest X-ray. Bone scintigraphy was carried out with 10 mCi Tc-99m methylene diphosphonate and the axial skeleton and femora were examined at two hours using either Searle LFOV or Pho Gamma III HP gamma camera. Skeletal survey was then performed if suspicious areas were seen. Tc-99m colloid liver scintigraphy (McCready & Newberry 1969) , grey-scale liver ultrasonography (Taylor et al. 1973 ) and iliac crest marrow aspirate were also carried out. If no evidence of metastases was detected in these ways, patients then underwent radical mastectomy (lateral or central carcinomas). All patients with medial tumours or tumours with ipsilateral axillary lymph node involvement had local radiotherapy. Patients with advanced unresectable carcinomas were biopsied and received either local radiotherapy or endocrine treatment. Of the entire group of 297 patients studied, 204 underwent ipsilateral axillary node biopsy or dissection. All nodes, the primary tumours and, where appropriate, the mastectomy specimens were examined histologically.
Methods

During the period from
Patients were then examined clinically at three-monthly intervals and all staging tests were repeated six-monthly in the poor-risk group (i.e. those with node involvement) or if symptoms and signs suggested metastatic disease in the remaining patients.
Tests for skeletal metastases were then evaluated longitudinally in 58 unselected patients, 22 of whom have developed skeletal metastases and 36 of whom have remained free from disease one year after the last scan was carried out. The results of bone scanning were reported as '0, 1, 2 or more than 2 hot spots' and each time a patient was scanned a radiological skeletal survey was carried out. No attempt was made to interpret the scan as being indicative of metastases or other disease.
In the retrospective study of tests for liver metastases, the notes of 51 patients who died with liver metastases proven at post-mortem were examined. 89 scintiscans and 80 ultrasound examinations had been carried out in these patients and 152 estimations of alkaline phosphatase within the year before death.
Results
Primary tumours and ipsilateral axillary node staging Two-hundred-and-ninety-seven patients were staged according to UICC TNM staging criteria. Two had TO (impalpable) primary tumours, 46 (15.6%) had Ti (21 with palpable axillary nodes), 93 (31.3%) had T2 (53 with palpable nodes), 65 (21.9%) had T3 tumours (42 with palpable nodes) and 88 patients (29.7%) had T4 tumours (61 with palpable nodes). Of those with T4 tumours, 8 were classified as T4a, 38 as T4b and 42 as T4c primary tumours. Three patients had bilateral primary tumours. Histologically, 283 of the 297 tumours were classified as infiltrating duct carcinomas, 6 as colloid carcinomas and 4 as medullary carcinomas. Two were examples of cystosarcoma phylloides and two lobular carcinoma in situ. Ipsilateral axillary node biopsy and dissection with histological examination revealed nodal involvement by tumour in 95 of 204 patients. (Table 1) Thirty-four patients presented with overt metastases at the time of their initial presentation. All were confirmed (except in the case of multiple osteolytic metastases or multiple pulmonary metastases) histologically or cytologically. The apparent detection rates for each of the tests varied from 6.1% (chest X-ray) to 0.4% (marrow aspirate) and are shown in Table 1 and liver imaging techniques were abnormal, but not diagnostic of metastases in some patients.
Physical testsfor metastases
The bone scans that were interpreted as indicative of metastases were proven to be correct when radiological skeletal survey was carried out at the time (9 patients) or subsequently (3 patients). Radiological skeletal surveys were carried out in 77 of the 89 patients who had bone scans that were considered 'suspicious'. Thirty-eight showed degenerative disease and 27 were normal. Two showed the presence of metastases and a further 4 showed Paget's disease. Other benign bone disease was present in the remaining 6 patients.
Eleven (12.5%) of 89 patients with 'suspicious' bone scans have subsequently developed metastases, compared with 27 (14.4%) of 188 with normal scans. Actuarial survival of a larger number of patients with suspect scans has been carried out and it seems, however, that a suspect scan may have prognostic significance. Further studies are being carried out to define this group (T J Powles & J Milan, in preparation). Four (21%) of 19 with 'suspicious' liver ultrasound examinations developed generalized metastases compared with 46 (19%) of the 238 patients with normal ultrasound scans. However, 6 (24%) of the 25 with 'suspicious' liver scintigrams developed generalized metastases compared to 24 (14%) of 168 with normal scintigrams, suggesting a better prognosis for patients with normal scans, but this difference is not statistically significant.
In the 34 patients who were shown to have metastases, a combination of chest X-ray and clinical examination for skin and node (other than ipsilateral) metastases (Table 1) would have detected 28 (82%) of these patients. Combined with bone scanning, 33 (97%) of the 34 patients would have been detected.
Fifty-one (19.4%) of the remaining 263 patients have subsequently developed metastatic disease at any site as detected by these tests and the sites of metastases are similar to those presenting with metastatic disease, with 38 of 51 (75%/) having metastases apparent on chest X-ray and/or clinical examination for skin and node metastases at first presentation. Combined with bone scans, 45 (88%) of 51 patients would have been detected.
Many of the 34 patients who were found to have metastases at first presentation had advanced primary tumours. Five had T3 tumours and 5 had T4a or T4b tumours; 18 had T4c tumours. The remaining 6 patients had T2 tumours.
Biochemical tests (Table 2) The 'normal' or 'non-diagnostic' ranges for each test were obtained from a previous study . Individually, biochemical tests disclosed abnormalities in 5.9-10.9% of patients, although the predictive value for each test in those without overt metastases was poor for each marker. A possible exception to this was alkaline phosphatase, since 3 of 7 patients with serum alkaline phosphatase in excess of 155 iu/l at presentation subsequently developed metastases. By combining alkaline phosphatase and y-glutamyl transpeptidase with chest Xray and clinical examination, 31 of 34 (93%) would have been detected at presentation and 45 (88%) of the 51 who subsequently developed metastases would have been detected at first presentation with metastatic disease. Figure 1 depicts the results of regular bone scanning in 22 patients who developed skeletal metastases following mastectomy and in 36 patients who remain disease-free. In those who developed skeletal metastases, a similar percentage of patients had abnormal scans until within 6 months of developing radiologically-obvious metastases. At varying times in the 6 months prior to overt metastases, 75% of scans became abnormal (range 0-6 months: mean 2.3 months). Three (14%) of the 22 patients did not develop a positive bone scan until after radiologically-obvious skeletal surveys showed evidence of metastatic disease. Of those who do develop clearly abnormal scans (i.e. > 2 hot spots), the majority do so only at the time of metastases. Thus, only 4 of 22 patients had scans showing > 2 hot spots prior to radiologicallyobvious disease.
As can be seen from Figure IB , a number of patients have scans showing 1 or 2 hot spots but have failed to develop obvious disease. Only 3 patients have shown >2 hot spots without developing subsequent disease. Figure 2 shows the proportion of tests suggesting metastases in the 51 patients studied within one year of death. Compared with alkaline phosphatase estimations, a small proportion of liver scintiscans or ultrasounds were abnormal before death. Thus, of the scintiscans carried out, only 11 of 57 (19.2%) were positive from 12-13 months before death, rising to 20 of 32 (62.5%) positive within 3 months of death. For the ultrasound examinations, 14 of 50 (28%) were positive up to three months before death, rising to 23 of 50 (76.7%) positive within 3 months of death.
'Lead intervals'for liver imaging tests
The weights of the livers and the distribution of the metastases were then examined in the patients whose metastases were detected by physical means and compared to those who were 51)0 UJtotal alkaline phosPhatase [11] [12] 9-10 7-8 5-6 3-4 1-2 within 2 weeks Time (months) prior to death with liver metastases Total no. 9 7 11 11 10 16 11 9 13 15 16 21 11 8 20 26 22 36 6 8 35 Figure 2 . Percentage of patients with positive tests for liver metastases prior to death. Total numbers of tests carried out indicated at foot of diagram not. Although the weights were similar, there was a larger number (13.4% compared with 7.5%) of patients with 'minimal liver involvement' amongst those whose deposits escaped detection.
In these 51 patients, liver scintiscan and ultrasound were carried out concomitantly in 68 instances and the results were identical on 56 occasions. In the remaining 12 occasions, there was no advantage for either scan or ultrasound, since 6 patients showed positive scans and 6 positive ultrasounds.
The values for alkaline phosphatase were found to rise progressively in these patients throughout the year prior to death (Figure 2 ).
Discussion
Our aim in this study was to compare the efficiency of some physical tests most commonly used to detect metastases in the same group of patients, emphasizing tests for bone and liver involvement.
Patients attending a single clinic between 1974-1977 were chosen as this could provide us with an unselected group who had been staged, treated in a uniform manner and observed closely with three-monthly follow up for at least two years since primary treatment. In this manner the predictive ability of the various tests, in particular 'borderline' ones, could be assessed.
As with our concomitant search for biochemical markers in this neoplasm (Coombes et al. 1977 , physical tests have failed to detect metastases in all but the few patients presenting with advanced malignancies. Thus, in our patients the bone and liver imaging tests disclosed metastases in only 1.2-4.2% and chest X-ray in only 6.1%. Bone marrow examination was positive in only a single patient at primary presentation with breast cancer, and this patient had advanced metastatic disease.
The results of bone scintigraphy were the most surprising, since recent studies have suggested a major role for this technique in detecting those with metastases (British Breast Group 1978) . Only 12 patients had definite scan evidence of bone metastases, but it is possible that more detailed analysis of bone scanning may reveal a subset of patients who have a poor prognosis. Such a study, using computer analysis, is being undertaken (T J Powles & J Milan, in preparation). In the meantime, however, a bone scan, liver ultrasound or liver scan that is 'possibly' abnormal, but not clearly suggestive of metastases, should not discourage a surgeon from adequate primary treatment since these tests often appear abnormal without implying the presence of metastatic disease.
Of the biochemical tests carried out in these patients, alkaline phosphatase and -y-glutamyl transpeptidase seem most useful, although the latter was measured only in the last two years of the study, and a further biochemical survey has already been carried out by our group .
Imaging tests for bone and liver metastases were then studied in greater depth in patients with definite evidence of bone and liver metastases respectively. The results indicate that bone scanning can give a 'lead interval' of up to 6 months in a proportion of patients, but in the majority the test becomes clearly indicative of metastases only at the time of radiological bone metastases. In a proportion of patients, therefore, the bone scan will be useful in delineating bone metastases early in the course of the disease. This study has not taken site of isotope uptake into consideration as this has been considered elsewhere (T J Powles & J Milan, in preparation).
Liver imaging tests are less frequently abnormal until a high index of suspicion exists for the presence of liver metastases. The majority of patients will only show a positive liver scan or ultrasound shortly before death. Therefore, since 70-80% of patients dying with breast carcinoma have liver deposits at death, negative imaging tests do not rule out the presence of metastatic disease.
Clearly, more sensitive staging tests are required to detect disease in patients with breast cancer. Our current studies include a continued search for biochemical indices of metastases, and hopefully such tests will improve our management of these patients. Concerning imaging tests, we feel that two approaches are worthy of further study. Firstly, we hope to improve tumour localization in a manner analogous to Goldenberg et al. (1978) who used labelledantisera to carcinoembryonic antigen (CEA) and subsequent scanning, with limited success in breast carcinoma. We hope to obtain more specific antisera to the tumour cell surface in order to achieve more accurate localization. Secondly, we wish to determine whether any differences in cell-surface structure occur at different metastatic sites in breast carcinoma, as has been suggested by Fidler & Nicolson (1976) for experimental tumour systems. Such differences might enable identification and detection of breast cancer cells to be carried out more efficiently. Thirdly, we are exploring methods of examining large amounts of bone marrow for the presence of malignant cells using immunocytochemistry (Ormerod et al. 1980 ) employing antisera to the milk fat globule membrane. Hopefully these methods will eventually find clinical application in the management of our patients.
